WO2008049070A3 - Il-17c antagonists and methods of using the same - Google Patents

Il-17c antagonists and methods of using the same Download PDF

Info

Publication number
WO2008049070A3
WO2008049070A3 PCT/US2007/081812 US2007081812W WO2008049070A3 WO 2008049070 A3 WO2008049070 A3 WO 2008049070A3 US 2007081812 W US2007081812 W US 2007081812W WO 2008049070 A3 WO2008049070 A3 WO 2008049070A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antagonists
methods
antagonizing
same
Prior art date
Application number
PCT/US2007/081812
Other languages
French (fr)
Other versions
WO2008049070A9 (en
WO2008049070A2 (en
Inventor
Mark W Appleby
Mark W Rixon
Kenneth B Lewis
Zeren Gao
Rolf E Kuestner
Carl W Birks
Original Assignee
Zymogenetics Inc
Mark W Appleby
Mark W Rixon
Kenneth B Lewis
Zeren Gao
Rolf E Kuestner
Carl W Birks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Mark W Appleby, Mark W Rixon, Kenneth B Lewis, Zeren Gao, Rolf E Kuestner, Carl W Birks filed Critical Zymogenetics Inc
Priority to EP07863429A priority Critical patent/EP2064237A2/en
Priority to CA002666842A priority patent/CA2666842A1/en
Publication of WO2008049070A2 publication Critical patent/WO2008049070A2/en
Publication of WO2008049070A9 publication Critical patent/WO2008049070A9/en
Publication of WO2008049070A3 publication Critical patent/WO2008049070A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates IL-17RE antagonists, such as soluble receptors and anti-IL-17RE antibodies, which are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. IL-17RE is a receptor for IL-17C. The present invention includes soluble IL-17RE, soluable fusion peptide comprising one or more IL-17RE domains anti-IL-17RE antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
PCT/US2007/081812 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same WO2008049070A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07863429A EP2064237A2 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same
CA002666842A CA2666842A1 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US82997206P 2006-10-18 2006-10-18
US60/829,972 2006-10-18
US86463306P 2006-11-07 2006-11-07
US60/864,633 2006-11-07
US86789306P 2006-11-30 2006-11-30
US60/867,893 2006-11-30
US89077607P 2007-02-20 2007-02-20
US60/890,776 2007-02-20
US91740407P 2007-05-11 2007-05-11
US60/917,404 2007-05-11

Publications (3)

Publication Number Publication Date
WO2008049070A2 WO2008049070A2 (en) 2008-04-24
WO2008049070A9 WO2008049070A9 (en) 2008-07-10
WO2008049070A3 true WO2008049070A3 (en) 2008-09-18

Family

ID=39226684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081812 WO2008049070A2 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same

Country Status (3)

Country Link
EP (1) EP2064237A2 (en)
CA (1) CA2666842A1 (en)
WO (1) WO2008049070A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP5607530B2 (en) 2007-09-04 2014-10-15 コンピュゲン エルティーディー． Polypeptides and polynucleotides and their use as drug targets for drug and biologics production
MA33989B1 (en) 2010-01-15 2013-02-01 Kirin Amgen Inc ANTIBODY FORMULATION AND THERAPEUTIC REGIMES
EP3214442A1 (en) * 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2012324895B2 (en) * 2011-10-19 2017-03-16 Galapagos Nv Antagonists of IL17C for the treatment of inflammatory disorders
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
EP2858670B8 (en) * 2012-06-12 2018-09-12 Orega Biotech Antagonists of il-17 isoforms and their uses
EP3359161A1 (en) * 2015-10-05 2018-08-15 MorphoSys AG Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
CU20180087A7 (en) 2016-02-19 2019-03-04 Galapagos Nv ANTIBODIES FOR IL-17-C

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044840A2 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044840A2 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI TIE-SHI ET AL: "Identification and functional characterization of a novel interleukin 17 receptor: A possible mitogenic activation through ras/mitogen-activated protein kinase signaling pathway", CELLULAR SIGNALLING, vol. 18, no. 8, August 2006 (2006-08-01), pages 1287 - 1298, XP002476196, ISSN: 0898-6568 *

Also Published As

Publication number Publication date
CA2666842A1 (en) 2008-04-24
EP2064237A2 (en) 2009-06-03
WO2008049070A9 (en) 2008-07-10
WO2008049070A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2005123778A3 (en) Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
HK1110333A1 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2004085476A3 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006044840A8 (en) Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007038703A3 (en) Il-17a and il-17f antagonists and methods of using the same
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2004078114A3 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
WO2007143168A3 (en) High affinity antibodies to human il-6 receptor
WO2009136286A3 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2007114861A3 (en) Il-21 receptor antagonists
EP2526968A3 (en) Nogo receptor antagonists
SG135207A1 (en) Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2006028810A3 (en) Method of wound healing using a2b adenosine receptor antagonists
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2007033140A3 (en) Prok2 antagonists and methods of use
WO2007089899A3 (en) Water-soluble (g protein)-coupled receptor protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07863429

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007863429

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009533531

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2666842

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP